Comparative Pharmacology
Head-to-head clinical analysis: CLORPRES versus METATENSIN 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLORPRES versus METATENSIN 2.
CLORPRES vs METATENSIN #2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CLORPRES is a combination of clonidine (alpha-2 adrenergic agonist that reduces sympathetic outflow) and chlorthalidone (thiazide diuretic that inhibits sodium reabsorption in distal tubules).
METATENSIN #2 contains reserpine and methyclothiazide. Reserpine inhibits vesicular monoamine transporter (VMAT), depleting catecholamines from peripheral neurons. Methyclothiazide inhibits sodium-chloride symporter in distal convoluted tubule, reducing fluid volume.
One tablet (clonidine 0.1 mg/chlorthalidone 15 mg) orally once or twice daily; maximum 0.6 mg clonidine/90 mg chlorthalidone daily.
1-2 tablets orally every 12 hours; each tablet contains reserpine 0.1 mg, hydralazine 25 mg, hydrochlorothiazide 15 mg.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours; may be prolonged in renal impairment, requiring dose adjustment.
12 hours (terminal); clinical context: twice-daily dosing maintains stable plasma levels
Renal excretion accounts for approximately 50% of elimination, with 30% as unchanged drug and 20% as metabolites; biliary/fecal elimination accounts for about 10%.
Renal (80% unchanged, 15% as glucuronide metabolite); biliary/fecal (5%)
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination